RU96102001A - IMIDES AS TNF ALPHA INHIBITORS - Google Patents
IMIDES AS TNF ALPHA INHIBITORSInfo
- Publication number
- RU96102001A RU96102001A RU96102001/04A RU96102001A RU96102001A RU 96102001 A RU96102001 A RU 96102001A RU 96102001/04 A RU96102001/04 A RU 96102001/04A RU 96102001 A RU96102001 A RU 96102001A RU 96102001 A RU96102001 A RU 96102001A
- Authority
- RU
- Russia
- Prior art keywords
- carbon atoms
- alkyl
- compound according
- alkoxy
- trifluoromethyl
- Prior art date
Links
- 150000003949 imides Chemical class 0.000 title 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 title 1
- 125000004432 carbon atoms Chemical group C* 0.000 claims 94
- -1 carbethoxy, carbmethoxy, carbpropoxy, acetyl Chemical group 0.000 claims 82
- 150000001875 compounds Chemical class 0.000 claims 62
- 125000000217 alkyl group Chemical group 0.000 claims 51
- 125000003545 alkoxy group Chemical group 0.000 claims 31
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 29
- 125000005843 halogen group Chemical group 0.000 claims 28
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 28
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 27
- 125000004093 cyano group Chemical group *C#N 0.000 claims 27
- 229910052739 hydrogen Inorganic materials 0.000 claims 24
- 239000001257 hydrogen Substances 0.000 claims 24
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 24
- 125000001424 substituent group Chemical group 0.000 claims 24
- 150000002431 hydrogen Chemical class 0.000 claims 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 15
- 125000004076 pyridyl group Chemical group 0.000 claims 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 10
- 230000002401 inhibitory effect Effects 0.000 claims 10
- 125000001624 naphthyl group Chemical group 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 9
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 9
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 8
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 8
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N Glutarimide Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 241001430294 unidentified retrovirus Species 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 4
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N Carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 3
- 238000009835 boiling Methods 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- QGLQAPPNLSDXHB-UHFFFAOYSA-N 2-(1,3-dioxoisoindol-2-yl)-3-phenylpropanamide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C(C(=O)N)CC1=CC=CC=C1 QGLQAPPNLSDXHB-UHFFFAOYSA-N 0.000 claims 1
- QBVWMDSGGHHFIN-LZUTUTKMSA-N 2-[[(Z)-[7-[(8Z)-8-[[(1,3-dioxoisoindol-2-yl)amino]methylidene]-1,6-dihydroxy-3-methyl-7-oxo-5-propan-2-ylnaphthalen-2-yl]-3,8-dihydroxy-6-methyl-2-oxo-4-propan-2-ylnaphthalen-1-ylidene]methyl]amino]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1N\C=C(C1=C2O)/C(=O)C(O)=C(C(C)C)C1=CC(C)=C2C(C(O)=C12)=C(C)C=C1C(C(C)C)=C(O)C(=O)\C2=C/NN1C(=O)C2=CC=CC=C2C1=O QBVWMDSGGHHFIN-LZUTUTKMSA-N 0.000 claims 1
- DOZZSWAOPDYVLH-UHFFFAOYSA-N 2-phenylpropanamide Chemical compound NC(=O)C(C)C1=CC=CC=C1 DOZZSWAOPDYVLH-UHFFFAOYSA-N 0.000 claims 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical group OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 claims 1
- VUAMNSYJJRFBMG-UHFFFAOYSA-N 5-(2,6-dioxopiperidin-3-yl)-1H-pyrrolo[3,4-d]imidazole-4,6-dione Chemical compound O=C1C=2NC=NC=2C(=O)N1C1CCC(=O)NC1=O VUAMNSYJJRFBMG-UHFFFAOYSA-N 0.000 claims 1
- QQNDEDWAPQTWHF-UHFFFAOYSA-N 6-(2,6-dioxopiperidin-3-yl)pyrrolo[3,4-b]pyridine-5,7-dione Chemical compound O=C1C2=NC=CC=C2C(=O)N1C1CCC(=O)NC1=O QQNDEDWAPQTWHF-UHFFFAOYSA-N 0.000 claims 1
- IVUJJWIVXRGSCE-UHFFFAOYSA-N N-(2,6-dioxopiperidin-3-yl)benzenesulfonamide Chemical compound O=C1NC(=O)CCC1NS(=O)(=O)C1=CC=CC=C1 IVUJJWIVXRGSCE-UHFFFAOYSA-N 0.000 claims 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N Phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M Sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- 229960003433 Thalidomide Drugs 0.000 claims 1
- 125000001980 alanyl group Chemical group 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000000637 arginyl group Chemical group 0.000 claims 1
- 125000004429 atoms Chemical group 0.000 claims 1
- 125000004802 cyanophenyl group Chemical group 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 125000000487 histidyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000000741 isoleucyl group Chemical group 0.000 claims 1
- 229950003188 isovaleryl diethylamide Drugs 0.000 claims 1
- 125000001998 leucyl group Chemical group 0.000 claims 1
- 125000001288 lysyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002073 methionyl group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 125000002072 seryl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001239 threonyl group Chemical group 0.000 claims 1
- 125000002233 tyrosyl group Chemical group 0.000 claims 1
- 125000002114 valyl group Chemical group 0.000 claims 1
- SXPUVBFQXJHYNS-UHFFFAOYSA-N α-Furil Chemical compound C=1C=COC=1C(=O)C(=O)C1=CC=CO1 SXPUVBFQXJHYNS-UHFFFAOYSA-N 0.000 claims 1
Claims (1)
в котором R1 означает двухвалентный остаток (I) 3,4-пиридина, (II) пирролидина, (III) имидазола, (IV) нафталина, (V) тиофена, или (VI) линейного или разветвленного алкана с 2 - 6 атомами углерода, незамещенного или замещенного на фенил или фенил с заместителями нитро, циано, трифторметил, карбэтокси, карбметокси, карбпропокси, ацетил, карбамил, ацетокси, карбокси, гидрокси, амино, алкил с 1 - 4 атомами углерода, алкокси с 1 - 4 атомами углерода, или гало, в которых валентные связи указанного остатка находятся у вицинальных атомов углерода в кольце R2 означает -CO- или SO2, и имеет значения 1, 2 или 3.2. The compound of the formula
in which R 1 means the divalent residue (I) of 3,4-pyridine, (II) pyrrolidine, (III) imidazole, (IV) naphthalene, (V) thiophene, or (VI) linear or branched alkane with 2 to 6 carbon atoms unsubstituted or substituted by phenyl or phenyl with substituents nitro, cyano, trifluoromethyl, carbethoxy, carbmethoxy, carbpropoxy, acetyl, carbamyl, acetoxy, carboxy, hydroxy, amino, alkyl with 1-4 carbon atoms, alkoxy with 1-4 carbon atoms, or halo, in which the valence bonds of this residue are located at the vicinal carbon atoms in the ring R 2 means -CO- and whether SO 2 , and matters 1, 2 or 3.
в котором R3 означает (I) фенил, замещенный 1 - 3 заместителями, каждый из которых выбирается независимо из ряда: нитро, циано, трифторметил, карбэтокси, карбметокси, карбпропокси, ацетил, карбамоил, ацетокси, карбокси, гидрокси, амино, алкил с 1 - 4 атомами углерода, алкокси с 1 - 4 атомами углерода или гало, (II) пиридил, (III) пирролил (IV) имидазолил, (V) нафтил, (VI) тиенил, (VII) хинолил, (VIII) фурил или (IX) индолил; и n имеет значение 1, 2 или 3.10. The compound of the formula
in which R 3 means (I) phenyl, substituted by 1 to 3 substituents, each of which is selected independently from the series: nitro, cyano, trifluoromethyl, carbethoxy, carbmethoxy, carbpropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl with 1 to 4 carbon atoms, alkoxy with 1 to 4 carbon atoms or halo, (II) pyridyl, (III) pyrrolyl (IV) imidazolyl, (V) naphthyl, (VI) thienyl, (VII) quinolyl, (VIII) furyl or (Ix) indolyl; and n is 1, 2 or 3.
в котором R4 означает аланил, аргинил, глицил, фенилглицил, гистидил, лейцил, изолейцил, лизил, метионил, пролил, саркозил, серил, гомосерил, треонил, тиронил, тирозил, валил, бензимидол-2-ил, бензксазол-2-ил, фенилсульфонил, метилфенилсульфонил, или фенилкарбамоил, а n имеет значение 1, 2 или 3.22. Compounds of the formula:
in which R 4 means alanyl, arginyl, glycyl, phenylglycyl, histidyl, leucyl, isoleucyl, lysyl, methionyl, shed, sarcosyl, seryl, homocerol, threonyl, tironil, tyrosyl, valyl, benzimidol-2-yl, benzazol-2-yl , phenylsulfonyl, methylphenylsulfonyl, or phenylcarbamoyl, and n is 1, 2, or 3.
в котором R5 означает (I) O-фенил, незамещенный или замещенный с 1 - 3 заместителями, каждый из которых выбирается независимо из нитро, циано, трифторметил, карбэтокси, карбметокси, карбпропиокси, ацетил, карбамоил, ацетокси, карбокси, гидрокси, амино, алкил с 1 - 4 атомами углерода, алкокси с 1 - 4 атомами углерода или гало, или (II) двухвалентный остаток пиридина, пирролидина, имидазола, нафталина или тиофена - две валентности которых находятся у двух вицинальных атомов углерода в цикле;
R6 означает -CO-, -CH2- или -SO2-;
R7 означает (I) водород, если R6 означает SO2-, (II) линейный, разветвленный или циклический алкил с 1 - 12 атомами углерода, (III) пиридил, (IV), фенил или замещенный фенил с одним или более заместителей, каждый из которых выбирается независимо из ряда нитро, циано, трифторметил, карбэтокси, карбметокси, карбпропокси, ацетил, карбамоил, ацетокси, карбокси, гидрокси, амино, алкил с 1 - 10 атомами углерода, алкокси с 1 - 10 атомами углерода, или гало, (V) бензил незамещенный или замещенный с 1 - 3 заместителями, выбранными из группы: нитро, циано, трифторметил, карбэтокси, карбметокси, карбпропокси, ацетил, карбамоил, ацетокси, карбокси, гидрокси, амино, алкил с 1 - 4 атомами углерода, алкокси с 1 - 4 атомами углерода, или гало, (VI) нафтил, (VII) бензилокси, или (VIII) имидазол -4-илметил. R12 означает OH, алкокси с 1 - 12 атомами углерода, -O-CH2-пиридил, -O- бензил или
где n имеет значение 0, 1, 2 или 3;
R8' - водород или алкил с 1 - 10 атомами углерода и
R9' - водород, алкил с 1 - 10 атомами углерода, -CH2- пиридил, бензил, -COR10, или -SO2R10, в котором
R10 означает водород, алкил с 1 - 4 атомами углерода или фенил.26. The compound of the formula:
in which R 5 means (I) O-phenyl, unsubstituted or substituted with 1 to 3 substituents, each of which is selected independently from nitro, cyano, trifluoromethyl, carbethoxy, carbmethoxy, carbpropioxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino , alkyl with 1-4 carbon atoms, alkoxy with 1-4 carbon atoms or halo, or (II) a divalent residue of pyridine, pyrrolidine, imidazole, naphthalene or thiophene - two valences of which are on two vicinal carbon atoms in the cycle;
R 6 means -CO-, -CH 2 - or -SO 2 -;
R 7 means (I) hydrogen, if R 6 means SO 2 -, (II) linear, branched or cyclic alkyl with 1 to 12 carbon atoms, (III) pyridyl, (IV), phenyl or substituted phenyl with one or more substituents , each of which is chosen independently from the series of nitro, cyano, trifluoromethyl, carbethoxy, carbmethoxy, carbpropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl with 1-10 carbon atoms, alkoxy with 1-10 carbon atoms, or halo , (V) benzyl unsubstituted or substituted with 1–3 substituents selected from the group: nitro, cyano, trifluoromethyl, carbeto xy, carbmethoxy, carbpropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl with 1-4 carbon atoms, alkoxy with 1-4 carbon atoms, or halo, (VI) naphthyl, (VII) benzyloxy, or (VIII a) imidazole-4-ylmethyl. R 12 means OH, alkoxy with 1 to 12 carbon atoms, —O — CH 2 -pyridyl, —O— benzyl or
where n is 0, 1, 2 or 3;
R 8 ' is hydrogen or alkyl with 1 to 10 carbon atoms and
R 9 ' is hydrogen, alkyl with 1-10 carbon atoms, -CH 2 - pyridyl, benzyl, -COR 10 , or -SO 2 R 10 , in which
R 10 means hydrogen, alkyl with 1 to 4 carbon atoms or phenyl.
в котором R5 означает (I) O-фенилен, незамещенный и замещенный с 1 - 3 заместителями, каждый из которых выбран независимо из нитро, циано, трифторметил, карбэтокси, карбметокси, карбпропокси, ацетил, карбамоил, ацетокси, карбокси, гидрокси, амино, алкил с 1 - 4 атомами углерода, алкокси с 1 - 4 атомами углерода, или гало, или (II) двухвалентный остаток пиридина, пирролидина, имидазола, нафталина или тиофена, в котором валентные связи находятся у вицинальных атомов углерода;
R6 означает -CO-, -CH2- или -SO2-;
R7 означает (I) водород, если R6 является -SO2-, (II) линейный, разветвленный или циклический алкил с 1 - 12 атомами углерода, (III) пиридил, (IV) фенил или замещенный фенил с одним или более заместителями, независимо от других выбираемыми из ряда нитро, циано, трифторметил, карбэтокси, карбметокси, карбпропокси, ацетил, карбамоил, ацетокси, карбокси, гидрокси, амино, алкил с 1 - 10 атомами углерода, алкокси с 1 - 10 атомами углерода, или гало, (V) алкил с 1 - 10 атомами углерода, (VI) бензил незамещенный или замещенный с 1 - 3 заместителями, выбранными из ряда нитро, циано, трифторметил, карбэтокси, карбметокси, карбпропокси, ацетил, карбамоил, ацетокси, карбокси, гидрокси, амино, алкил с 1 - 4 атомами углерода, алкокси с 1 - 4 атомами углерода, или гало (VII), нафтил, (VIII) бензилокси, или (IX) имидазол-4-илметил;
n имеет значение 0, 1, 2 или 3;
R8 означает водород или алкил с 1 - 10 атомами углерода; и R9 означает водород, алкил с 1 - 10 атомами углерода, - -CH2 - пиридил, бензил, -COR10 или -SO2R10, в которых R10 означает водород, алкил с 1 - 4 атомами углерода, или фенил.31. A method for reducing levels of TNF α in a mammal, which comprises administering an effective amount of a compound of formula:
in which R 5 means (I) O-phenylene, unsubstituted and substituted with 1 to 3 substituents, each of which is selected independently from nitro, cyano, trifluoromethyl, carbethoxy, carbmethoxy, carbpropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino , alkyl with 1-4 carbon atoms, alkoxy with 1-4 carbon atoms, or halo, or (ii) a divalent pyridine, pyrrolidine, imidazole, naphthalene or thiophene residue, in which the valence bonds are located at the vicinal carbon atoms;
R 6 means -CO-, -CH 2 - or -SO 2 -;
R 7 means (I) hydrogen, if R 6 is -SO 2 -, (II) linear, branched or cyclic alkyl with 1 to 12 carbon atoms, (III) pyridyl, (IV) phenyl or substituted phenyl with one or more substituents , independently of others, selected from the range of nitro, cyano, trifluoromethyl, carbethoxy, carbmethoxy, carbpropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl with 1-10 carbon atoms, alkoxy with 1-10 carbon atoms, or halo, (V) alkyl with 1 to 10 carbon atoms, (VI) benzyl unsubstituted or substituted with 1 to 3 substituents selected from the range of nitro, cyan , trifluoromethyl, carbethoxy, carbmethoxy, carbpropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl with 1-4 carbon atoms, alkoxy with 1-4 carbon atoms, or halo (VII), naphthyl, (VIII) benzyloxy, or (ix) imidazol-4-ylmethyl;
n is 0, 1, 2 or 3;
R 8 means hydrogen or alkyl with 1 to 10 carbon atoms; and R 9 means hydrogen, alkyl with 1-10 carbon atoms, - -CH 2 - pyridyl, benzyl, -COR 10 or -SO 2 R 10 , in which R 10 means hydrogen, alkyl with 1-4 carbon atoms, or phenyl .
37. Фармацевтическая композиция, содержащая соединение по п.10 в количестве, эффективном при одно- или многократном приеме для ингибирования TNFα.
38. Фармацевтическая композиция, содержащая соединение по п.22, в количестве, эффективном при одно- или многократном приеме для ингибирования TNFα.
39. Фармацевтическая композиция, содержащая соединение по п.26 в количестве, эффективном при одно- или многократном приеме для ингибирования TNFα.
40. Способ снижения уровня TNFα у млекопитающих, который включает прием эффективного количества соединения формулы
в котором R5 означает (1) O-фенилен, незамещенный или замещенный с 1 - 3 заместителями, каждый из которых выбирается независимо из нитро, циано, трифторметил, карбоэтокси, карбметокси, карбпропокси, ацетил, карбамоил, ацетокси, карбокси, гидрокси, амино, алкил с 1 - 4 атомами углерода, алкокси с 1 - 4 атомами углерода, или гало, или (II) двухвалентный остаток пиридина, пирролидина, имидазола, нафталина, или тиофена, в котором две валентные связи находятся у вицинальных атомов углерода в цикле;
R6 означает -CO-, -CH2- или -SO2-;
R7 означает (I) водород, если R6 означает -SO2-, (II) линейный, разветвленный или циклический алкил с 1 - 2 атомами углерода; (III) пиридил, (IV) фенил или замещенный фенил с одним или более заместителей, каждый из которых выбирается независимо от других из: нитро, циано, трифторметил; карбэтокси, карбметокси, карбпропокси, ацетил, карбамоил, ацетокси, карбокси, гидрокси, амино, алкил с 1 - 10 атомами углерода, алкокси с 1 - 10 атомами углерода, или гало; (V) алкил с 1 - 10 атомами углерода, (VI) бензил незамещенный или замещенный с одним - тремя заместителями, выбранными из группы, состоящей из нитро, циано, трифторметил, карбэтокси, карбметокси, карбпропокси, ацетил, карбамоил, ацетокси, карбокси, гидрокси, амино, алкил с 1 - 4 атомами углерода, алкокси с 1 - 4 атомами углерода, или гало, (VII) нафтил, (VIII) бензилокси или (IX) имидазол-4-илметил;
R12 означает OH, алкокси с 1 - 12 атомами углерода, -O-CH2 - пиридил, -O - бензил, или
n имеет значение 0, 1, 2 или 3,
R8' означает водород или алкил с 1 - 10 атомами углерода;
R9' означает водород или алкил с 1 - 10 атомами углерода, -CH2 - пиридил, бензил, -COR10, или -SO2R10, в которых R10 означает водород, алкил с 1 - 4 атомами углерода или фенил.36. A pharmaceutical composition comprising a compound according to claim 2 in an effective amount at single or multiple dose for the inhibition of TNF α.
37. A pharmaceutical composition comprising a compound according to claim 10 in an amount effective at single or multiple dose for the inhibition of TNF α.
38. A pharmaceutical composition comprising a compound according to claim 22 in an amount effective at single or multiple dose for the inhibition of TNF α.
39. A pharmaceutical composition comprising a compound according to claim 26 in an amount effective at single or multiple dose for the inhibition of TNF α.
40. A method for reducing levels of TNF α in a mammal, which comprises administering an effective amount of a compound of formula
in which R 5 means (1) O-phenylene, unsubstituted or substituted with 1 to 3 substituents, each of which is selected independently from nitro, cyano, trifluoromethyl, carboethoxy, carbmethoxy, carbpropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino , alkyl with 1-4 carbon atoms, alkoxy with 1-4 carbon atoms, or halo, or (ii) a divalent residue of pyridine, pyrrolidine, imidazole, naphthalene, or thiophene, in which two valence bonds are located at the vicinal carbon atoms in the cycle;
R 6 means -CO-, -CH 2 - or -SO 2 -;
R 7 means (I) hydrogen, if R 6 means -SO 2 -, (II) linear, branched or cyclic alkyl with 1 to 2 carbon atoms; (Iii) pyridyl, (iv) phenyl or substituted phenyl with one or more substituents, each of which is chosen independently of the others from: nitro, cyano, trifluoromethyl; carbethoxy, carbmethoxy, carbpropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl with 1-10 carbon atoms, alkoxy with 1-10 carbon atoms, or halo; (V) alkyl with 1-10 carbon atoms, (VI) benzyl unsubstituted or substituted with one to three substituents selected from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbmethoxy, carbpropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl with 1-4 carbon atoms, alkoxy with 1-4 carbon atoms, or halo, (VII) naphthyl, (VIII) benzyloxy, or (IX) imidazol-4-ylmethyl;
R 12 is OH, alkoxy with 1 to 12 carbon atoms, —O — CH 2 is pyridyl, —O is benzyl, or
n is 0, 1, 2 or 3,
R 8 ' means hydrogen or alkyl with 1 to 10 carbon atoms;
R 9 ' means hydrogen or alkyl with 1 to 10 carbon atoms, -CH 2 - pyridyl, benzyl, -COR 10 , or -SO 2 R 10 , in which R 10 means hydrogen, alkyl with 1 to 4 carbon atoms or phenyl.
где R8 означает водород или алкил с 1 - 10 атомами углерода;
R9 означает водород, алкил с 1 - 10 атомами углерода; - CH2- пиридил, бензил, -COR10, или -SO2R10, в которых R10 означает водород, алкил с 1 - 10 атомами углерода или фенил.45. The compound according to claim 26, in which R 12 means
where R 8 means hydrogen or alkyl with 1 to 10 carbon atoms;
R 9 means hydrogen, alkyl with 1 to 10 carbon atoms; - CH 2 - pyridyl, benzyl, -COR 10 , or -SO 2 R 10 , in which R 10 means hydrogen, alkyl with 1 to 10 carbon atoms or phenyl.
где R8 означает водород или алкил с 1 - 10 атомами углерода;
R9 означает водород, алкил с 1 - 10 атомами углерода; -CH2- пиридил, бензил, -COR10 или -SO2R10, в которых R10 означает водород, алкил с 1 - 10 атомами углерода, или фенил; и где n имеет значение 1.46. The compound according to claim 26, in which R 5 means O-phenylene; R 6 means -CO-; P 7 means (I) linear, branched or cyclic alkyl with 1 to 12 carbon atoms, (II) pyridyl, (III) phenyl or substituted phenyl with one or more substituents, each of which is chosen independently from: nitro, cyano, trifluoromethyl, carbethoxy, carbmethoxy, carbpropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl with 1-10 carbon atoms, alkoxy with 1-10 carbon atoms, or halo, (V) benzyl unsubstituted or substituted with 1 - 3 substituents, selected from the group: nitro, cyano, trifluoromethyl, carbethoxy, carbmethoxy, carbpropoxy, acety l, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl with 1-4 carbon atoms, alkoxy with 1-4 carbon atoms, or halo, (VI) naphthyl, (VII) benzyloxy, or (VIII) imidazol-4-ylmethyl ; R 12 means
where R 8 means hydrogen or alkyl with 1 to 10 carbon atoms;
R 9 means hydrogen, alkyl with 1 to 10 carbon atoms; -CH 2 - pyridyl, benzyl, -COR 10 or -SO 2 R 10 , in which R 10 means hydrogen, alkyl with 1 to 10 carbon atoms, or phenyl; and where n is 1.
в которой R7 означает (I) линейный, разветвленный или циклический алкил с 1 - 2 атомами углерода; (II) пиридил; (III) фенил или замещенный фенил с одним из более заместителей, каждый из которых выбирается независимо из ряда: нитро, циано, трифторметил, карбметокси, карбэтокси, карбпропокси, ацетил, карбамоил, ацетокси, карбокси, гидрокси, амино, алкил с 1 - 4 атомами углерода, алкокси с 1 - 4 атомами углерода, или гало; (V) нафтил; (VI) бензилокси; или (VII) имидазол-4-илметил;
R12 означает алкокси с 1 - 12 атомами углерода, -O-CH2-пиридил, -O-бензил, или
R8 означает водород или алкил с 1 - 10 атомами углерода;
R9 означает водород, алкил с 1 - 10 атомами углерода, -COR10, -SO2R10, в которых R10 означает водород, алкил с 1 - 4 атомами углерода или фенил.56. The compound of the formula:
in which R 7 means (I) linear, branched or cyclic alkyl with 1 to 2 carbon atoms; (Ii) pyridyl; (Iii) phenyl or substituted phenyl with one of the more substituents, each of which is independently selected from the series: nitro, cyano, trifluoromethyl, carbmethoxy, carbethoxy, carbpropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl with 1-4 carbon atoms, alkoxy with 1 to 4 carbon atoms, or halo; (V) naphthyl; (Vi) benzyloxy; or (VII) imidazol-4-ylmethyl;
R 12 means alkoxy with 1 to 12 carbon atoms, -O-CH 2 -pyridyl, -O-benzyl, or
R 8 means hydrogen or alkyl with 1 to 10 carbon atoms;
R 9 means hydrogen, alkyl with 1-10 carbon atoms, -COR 10 , -SO 2 R 10 , in which R 10 means hydrogen, alkyl with 1-4 carbon atoms or phenyl.
в котором R7 означает (I) линейный, разветвленный или циклический алкил с 1 - 12 атомами углерода; (II) пиридил; (III) фенил или замещенный фенил с одним или более заместителей, каждый из которых выбран независимо из ряда: нитро, циано, трифторметил, карбэтокси, карбметокси, карбпропокси, ацетил, карбамоил, ацетокси, карбокси, гидрокси, амино, алкил с 1 - 10 атомами углерода, алкокси с 1 - 10 атомами углерода, или гало; (VI) бензил или замещенный бензил с одним - тремя заместителями, выбранными из группы: нитро, циано, трифторметил, карбэтокси, карбметокси, карбпропокси, ацетил, карбамоил, ацетокси, карбокси, гидрокси, амино, алкил с 1 - 4 атомами углерода, алкокси с 1 - 4 атомами углерода, или гало; (V) нафтил; (VI) бензилокси; или (VII) имидазол-4-илметил;
R12 означает алкокси с 1 - 12 атомами углерода, -O-CH2-пиридил, -O-бензил, или
где R8 означает водород или алкил с 1 - 10 атомами углерода;
R9 означает водород, алкил с 1 - 10 атомами углерода, -COR10, или -SO2R10, а R10 означает водород, алкил с 1 - 4 атомами углерода или фенил.57. A method for reducing levels of TNF α in a mammal, which comprises administering an effective amount of a compound of formula:
in which R 7 means (I) linear, branched or cyclic alkyl with 1 to 12 carbon atoms; (Ii) pyridyl; (III) phenyl or substituted phenyl with one or more substituents, each of which is independently selected from the series: nitro, cyano, trifluoromethyl, carbethoxy, carbmethoxy, carbpropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl with 1-10 carbon atoms, alkoxy with 1 to 10 carbon atoms, or halo; (VI) benzyl or substituted benzyl with one to three substituents selected from the group: nitro, cyano, trifluoromethyl, carbethoxy, carbmethoxy, carbpropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl with 1-4 carbon atoms, alkoxy with 1 to 4 carbon atoms, or halo; (V) naphthyl; (Vi) benzyloxy; or (VII) imidazol-4-ylmethyl;
R 12 means alkoxy with 1 to 12 carbon atoms, -O-CH 2 -pyridyl, -O-benzyl, or
where R 8 means hydrogen or alkyl with 1 to 10 carbon atoms;
R 9 is hydrogen, alkyl with 1-10 carbon atoms, -COR 10 , or -SO 2 R 10 , and R 10 means hydrogen, alkyl with 1-4 carbon atoms, or phenyl.
60. Соединение по п.26, которое означает 3-фталимидо-3-(3,4-диэтоксифенил)пропиоамид.59. A pharmaceutical composition comprising a compound according to claim 57 in an amount effective at single or multiple dose for the inhibition of TNF α.
60. The compound according to claim 26, which means 3-phthalimido-3- (3,4-diethoxyphenyl) propioamide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8751093A | 1993-07-02 | 1993-07-02 | |
US08/087,510 | 1993-07-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU96102001A true RU96102001A (en) | 1998-08-20 |
RU2174516C2 RU2174516C2 (en) | 2001-10-10 |
Family
ID=22205623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU96102001/04A RU2174516C2 (en) | 1993-07-02 | 1994-07-01 | Imides as tnf-alpha inhibitors |
Country Status (20)
Country | Link |
---|---|
US (1) | US5463063A (en) |
EP (5) | EP1004581B1 (en) |
JP (5) | JP3971794B2 (en) |
KR (1) | KR100401290B1 (en) |
AT (4) | ATE277036T1 (en) |
AU (1) | AU687843B2 (en) |
CA (3) | CA2626178A1 (en) |
CZ (2) | CZ294444B6 (en) |
DE (4) | DE69434645T2 (en) |
DK (4) | DK0706521T3 (en) |
ES (4) | ES2226696T3 (en) |
FI (2) | FI114984B (en) |
HK (3) | HK1025770A1 (en) |
HU (1) | HUT75312A (en) |
NZ (3) | NZ268812A (en) |
PL (1) | PL180377B1 (en) |
PT (4) | PT1004572E (en) |
RU (1) | RU2174516C2 (en) |
SK (1) | SK166595A3 (en) |
WO (1) | WO1995001348A2 (en) |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US5686436A (en) * | 1993-05-13 | 1997-11-11 | Hiv Diagnostics, Inc. | Multi-faceted method to repress reproduction of latent viruses in humans and animals |
RU2164514C2 (en) * | 1994-12-30 | 2001-03-27 | Селджин Корпорейшн | Imide/amide ethers, pharmaceutical composition based on thereof and method of decrease of fnok level in mammalian |
US5703098A (en) * | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US5801195A (en) | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
US5728845A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
US5658940A (en) * | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
DE19548378A1 (en) * | 1995-12-27 | 1997-07-03 | Bran & Luebbe | Process and device combination for establishing the comparability of spectrometer measurements |
DE69700616T2 (en) * | 1996-07-02 | 2000-03-16 | Nisshin Flour Milling Co | Imide derivatives |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
EP2070920B8 (en) * | 1996-07-24 | 2011-04-27 | Celgene Corporation | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels |
HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
EP2859895A1 (en) * | 1996-07-24 | 2015-04-15 | Celgene Corporation | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels |
EP1661566A3 (en) * | 1996-08-05 | 2008-04-16 | Myriad Genetics, Inc. | Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors |
DE69735545T2 (en) * | 1996-08-05 | 2006-08-10 | Myriad Genetics, Inc., Salt Lake City | USE OF BETA LEAF MIMETIKA AS A PROTEASE AND KINASE INHIBITOR AND ALSHEMMER OF A TRANSCRIPTION FACTOR |
DE69739181D1 (en) * | 1996-08-12 | 2009-02-05 | Celgene Corp | New immunotherapeutic agents and their use in reducing cytokine levels |
DE19703763C1 (en) * | 1997-02-01 | 1998-10-01 | Gruenenthal Gmbh | Thalidomide-analogous compounds from the class of the piperidine-2,6-diones |
KR19980074060A (en) * | 1997-03-21 | 1998-11-05 | 김윤배 | Novel substituted 3,4-dialkoxyphenyl derivatives |
DE69813876T2 (en) * | 1997-07-31 | 2004-01-29 | Celgene Corp | SUSSITITATED ALKANY HYDROXAMIC ACID AND METHOD FOR REDUCING TNF ALPHASIC MIRROR |
US6831057B2 (en) | 1997-10-28 | 2004-12-14 | The University Of North Carolina At Chapel Hill | Use of NF-κB inhibition in combination therapy for cancer |
US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
PT1308444E (en) * | 1997-11-18 | 2006-08-31 | Celgene Corp | 2- (2,6-DIOXO-3-FLUOROPIPERIDINE-3-IL) - ISOINDOLINS AND THEIR USE TO REDUCE TNF |
TR200101503T2 (en) | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2- (2,6-dioxopiperidin-3-yl) isoindoline derivatives, their preparation and use as inhibitors of inflammatory cytokines |
US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
DE19948126A1 (en) * | 1999-10-06 | 2001-04-12 | Max Delbrueck Centrum | Pharmaceutical agent for the treatment of cachexia and / or cardiogenic shock |
US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
US6670358B2 (en) * | 2000-05-16 | 2003-12-30 | Cephalon, Inc. | Substituted thioacetamides |
US8030343B2 (en) * | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
ES2172474B1 (en) * | 2001-03-01 | 2004-01-16 | Fundacion Universitaria San Pa | GLUTARIMIDE DERIVATIVES AS THERAPEUTIC AGENTS. |
US7153867B2 (en) * | 2001-08-06 | 2006-12-26 | Celgene Corporation | Use of nitrogen substituted thalidomide analogs for the treatment of macular degenerator |
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
EP1556033A4 (en) * | 2002-05-17 | 2006-05-31 | Celgene Corp | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
GB0215392D0 (en) * | 2002-07-03 | 2002-08-14 | Glaxo Group Ltd | Chemical compounds |
ZA200503024B (en) * | 2002-10-15 | 2006-11-29 | Celgene Corp | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
US20040087558A1 (en) | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
NZ564480A (en) | 2002-11-06 | 2008-12-24 | Celgene Corp | Use of selective cytokine inhibitory drugs for the treatment of Behcet's disease |
EP1569903A4 (en) * | 2002-11-06 | 2009-07-29 | Celgene Corp | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
JP2006510617A (en) * | 2002-11-18 | 2006-03-30 | セルジーン・コーポレーション | Method of using (+)-3- (3,4-dimethoxy-phenyl) -3- (1-oxo-1,3-dihydro-isoindol-2-yl) -propionamide and compositions containing it |
BR0316256A (en) * | 2002-11-18 | 2005-10-04 | Celgene Corp | Methods of inhibiting tnf-alpha production and pde4 activity, treating or preventing a disease or disorder, controlling camp levels in a cell and producing a compound, pharmaceutical composition and compound |
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
EP1605935A4 (en) * | 2003-03-06 | 2009-05-20 | Celgene Corp | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
DE602004032522D1 (en) * | 2003-03-12 | 2011-06-16 | Celgene Corp | ISOINDOLYL COMPOUNDS SUBSTITUTED WITH N-ALKYL HYDROXAMIC ACIDS AND THEIR PHARMACEUTICAL USE |
CN100427465C (en) * | 2003-03-12 | 2008-10-22 | 细胞基因公司 | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses |
EP1621529A4 (en) * | 2003-03-17 | 2007-10-17 | Ube Industries | 3-AMINO-3-ARYLPROPIONIC ACID n-ALKYL ESTERS, PROCESS FOR PRODUCTION THEREOF, AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-3-ARYLPROPIONIC ACIDS AND ESTERS OF THE ANTIPODES THERETO |
CN100398534C (en) * | 2003-09-15 | 2008-07-02 | 天津和美生物技术有限公司 | New method of synthesizing thalidomide and its derivative |
JP2007524656A (en) * | 2003-10-23 | 2007-08-30 | セルジーン・コーポレーション | Compositions comprising selective cytokine inhibitors for treating, modifying and managing pain and methods of use thereof |
US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
BRPI0508098A (en) | 2004-02-27 | 2007-07-17 | Amgen Inc | compounds, pharmaceutical compositions and methods for use in the treatment of metabolic disorders |
CA2563207A1 (en) * | 2004-04-14 | 2005-11-24 | Celgene Corporation | Use of selective cytokine inhibitory drugs in myelodysplastic syndromes |
ZA200609228B (en) * | 2004-04-23 | 2008-05-28 | Celgene Corp | Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension |
WO2005112918A1 (en) * | 2004-05-05 | 2005-12-01 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
MXPA06012701A (en) * | 2004-05-05 | 2007-02-14 | Celgene Corp | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases. |
ITMI20041113A1 (en) * | 2004-06-01 | 2004-09-01 | Antibioticos Spa | PROCESS FOR THE SYNTHESIS OF THE THALIDOMIDE |
US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
WO2006028964A1 (en) * | 2004-09-03 | 2006-03-16 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
AU2005302523A1 (en) * | 2004-10-28 | 2006-05-11 | Celgene Corporation | Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury |
US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
PT2380887E (en) * | 2005-06-30 | 2013-09-18 | Celgene Corp | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
EP1924546A1 (en) | 2005-09-14 | 2008-05-28 | Amgen, Inc | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
CN1939922B (en) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 5H-thiophene [3,4-C] pyrrole-4,6-diketone derivative for inhibiting cell release tumor necrosis factor |
GB0522460D0 (en) * | 2005-11-03 | 2005-12-14 | Prendergast Patrick T | Composition and method for the treatment of avian influenza |
EP2061760A1 (en) | 2006-09-07 | 2009-05-27 | Amgen, Inc | Benzo-fused compounds for use in treating metabolic disorders |
US7714008B2 (en) | 2006-09-07 | 2010-05-11 | Amgen Inc. | Heterocyclic GPR40 modulators |
CN101147743B (en) * | 2006-09-19 | 2010-10-06 | 浙江海正药业股份有限公司 | Application of ginsenoside Compound-K in pharmaceutical |
CN101186611B (en) * | 2006-11-15 | 2011-05-18 | 天津和美生物技术有限公司 | Pyrroline-2-one derivative capable of inhibiting cell to release tumor necrotic factor and its preparation and application |
US7750048B2 (en) | 2006-11-15 | 2010-07-06 | Janssen Pharmaceutica Nv | GPR40 agonists |
WO2008130514A1 (en) | 2007-04-16 | 2008-10-30 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
WO2009048527A1 (en) | 2007-10-10 | 2009-04-16 | Amgen Inc. | Substituted biphenyl gpr40 modulators |
WO2009111056A1 (en) | 2008-03-06 | 2009-09-11 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
US8748462B2 (en) | 2008-10-15 | 2014-06-10 | Amgen Inc. | Spirocyclic GPR40 modulators |
AU2010213936B2 (en) | 2009-02-10 | 2014-07-31 | Celgene Corporation | Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management of tuberculosis |
CA2794096A1 (en) | 2010-04-07 | 2011-10-13 | Celgene Corporation | Methods for treating respiratory viral infection |
US20130143923A1 (en) | 2010-06-09 | 2013-06-06 | Vinayak Govind Gore | Crystalline forms of thalidomide and processes for their preparation |
CN103026229B (en) | 2010-06-15 | 2016-03-30 | 细胞基因公司 | Be used for the treatment of psoriatic biomarker |
GB201018171D0 (en) | 2010-10-28 | 2010-12-08 | Givaudan Sa | Organic compounds |
MX2013010360A (en) | 2011-03-11 | 2014-04-14 | Celgene Corp | Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piper idine-2,6-dione, and their pharmaceutical compositions and uses. |
WO2014107622A1 (en) | 2013-01-07 | 2014-07-10 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
JP6513095B2 (en) | 2014-01-03 | 2019-05-15 | ユニバーシティ オブ サザン カリフォルニア | Heteroatom-containing deoxyuridine triphosphatase inhibitors |
EP3142663A1 (en) | 2014-05-16 | 2017-03-22 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
US10544105B2 (en) | 2015-07-08 | 2020-01-28 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
WO2017006270A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
US10570100B2 (en) | 2015-07-08 | 2020-02-25 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
EP3319939A1 (en) | 2015-07-08 | 2018-05-16 | CV6 Therapeutics (NI) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
WO2017070291A1 (en) | 2015-10-21 | 2017-04-27 | Celgene Corporation | Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris) |
CA3001799A1 (en) | 2015-10-21 | 2017-04-27 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
MX2018011216A (en) * | 2016-03-16 | 2019-08-29 | H Lee Moffitt Cancer Ct & Res | Small molecules against cereblon to enhance effector t cell function. |
WO2018098209A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
WO2018098204A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
WO2018098207A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
US10858344B2 (en) | 2016-11-23 | 2020-12-08 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
WO2018098208A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
EP3559005A1 (en) | 2016-12-21 | 2019-10-30 | Biotheryx Inc. | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
US11247984B2 (en) | 2017-01-05 | 2022-02-15 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
CN111278815B (en) * | 2017-09-04 | 2024-03-08 | C4医药公司 | Glutarimide |
CN107698484B (en) * | 2017-11-13 | 2020-05-19 | 广东中科药物研究有限公司 | Preparation method and application of lenalidomide derivative |
KR102646322B1 (en) * | 2018-04-17 | 2024-03-11 | 톈진 헤메이 파마슈티칼 컴퍼니 리미티드 | Isoindole derivatives |
US11730726B2 (en) | 2018-07-11 | 2023-08-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Dimeric immuno-modulatory compounds against cereblon-based mechanisms |
EP3830093A1 (en) | 2018-07-27 | 2021-06-09 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
US11897930B2 (en) | 2020-04-28 | 2024-02-13 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
CN112724024A (en) * | 2021-01-19 | 2021-04-30 | 宁波酶赛生物工程有限公司 | Synthetic method of R-benzylphenethylamine |
WO2022187423A1 (en) * | 2021-03-03 | 2022-09-09 | The Regents Of The University Of Michigan | Cereblon ligands |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB768821A (en) * | 1954-05-17 | 1957-02-20 | Gruenenthal Chemie | Novel products of the amino-piperidine-2, 6-dione series |
GB1036694A (en) * | 1964-03-03 | 1966-07-20 | Wyeth John & Brother Ltd | Substituted aminocarboxylic acid derivatives and compositions containing such derivatives |
GB1030030A (en) * | 1964-12-28 | 1966-05-18 | Vismara Francesco Spa | Derivatives of phthalimide |
AT278739B (en) * | 1966-11-08 | 1970-02-10 | Kwizda Fa F Johann | Process for the preparation of new anhydrides and imides of substituted dicarboxylic acids |
US3553217A (en) * | 1968-10-18 | 1971-01-05 | Aldrich Chem Co Inc | 2-(quinolinimido)glutarimide |
CH554837A (en) * | 1970-04-09 | 1974-10-15 | Ciba Geigy Ag | (+)-beta-amino-beta (3,4-dimethoxy-phenyl)-p - |
CH554833A (en) * | 1970-04-09 | 1974-10-15 | Ciba Geigy Ag | (+)-beta-amino-beta (3,4-dimethoxy-phenyl)-p - |
US4918193A (en) * | 1989-01-11 | 1990-04-17 | Burzynski Stanislaw R | Methods for preparing 3-[N-phenyl-acetylaminopiperidine]-2,6-dion |
GB9000644D0 (en) * | 1990-01-11 | 1990-03-14 | Erba Carlo Spa | New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds |
GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
WO1992014455A1 (en) * | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
-
1993
- 1993-10-20 US US08/140,237 patent/US5463063A/en not_active Expired - Lifetime
-
1994
- 1994-07-01 ES ES00200492T patent/ES2226696T3/en not_active Expired - Lifetime
- 1994-07-01 ES ES00200491T patent/ES2278574T3/en not_active Expired - Lifetime
- 1994-07-01 CZ CZ2003663A patent/CZ294444B6/en not_active IP Right Cessation
- 1994-07-01 DK DK94921439T patent/DK0706521T3/en active
- 1994-07-01 DE DE69434645T patent/DE69434645T2/en not_active Expired - Fee Related
- 1994-07-01 AU AU72167/94A patent/AU687843B2/en not_active Ceased
- 1994-07-01 SK SK1665-95A patent/SK166595A3/en unknown
- 1994-07-01 AT AT00200492T patent/ATE277036T1/en active
- 1994-07-01 PT PT00200498T patent/PT1004572E/en unknown
- 1994-07-01 NZ NZ268812A patent/NZ268812A/en not_active IP Right Cessation
- 1994-07-01 CA CA002626178A patent/CA2626178A1/en not_active Abandoned
- 1994-07-01 EP EP00200492A patent/EP1004581B1/en not_active Expired - Lifetime
- 1994-07-01 NZ NZ329259A patent/NZ329259A/en not_active IP Right Cessation
- 1994-07-01 EP EP04077075A patent/EP1477486A3/en not_active Withdrawn
- 1994-07-01 EP EP00200498A patent/EP1004572B1/en not_active Expired - Lifetime
- 1994-07-01 CA CA002166315A patent/CA2166315C/en not_active Expired - Fee Related
- 1994-07-01 AT AT00200491T patent/ATE348809T1/en not_active IP Right Cessation
- 1994-07-01 AT AT00200498T patent/ATE319678T1/en not_active IP Right Cessation
- 1994-07-01 JP JP50364895A patent/JP3971794B2/en not_active Expired - Fee Related
- 1994-07-01 RU RU96102001/04A patent/RU2174516C2/en not_active IP Right Cessation
- 1994-07-01 KR KR1019960700005A patent/KR100401290B1/en not_active IP Right Cessation
- 1994-07-01 EP EP94921439A patent/EP0706521B1/en not_active Expired - Lifetime
- 1994-07-01 NZ NZ329258A patent/NZ329258A/en not_active IP Right Cessation
- 1994-07-01 DE DE69434895T patent/DE69434895T2/en not_active Expired - Fee Related
- 1994-07-01 ES ES00200498T patent/ES2258956T3/en not_active Expired - Lifetime
- 1994-07-01 DK DK00200491T patent/DK1004580T3/en active
- 1994-07-01 DK DK00200492T patent/DK1004581T3/en active
- 1994-07-01 CA CA2531868A patent/CA2531868C/en not_active Expired - Lifetime
- 1994-07-01 CZ CZ9610A patent/CZ1096A3/en unknown
- 1994-07-01 EP EP00200491A patent/EP1004580B1/en not_active Expired - Lifetime
- 1994-07-01 PT PT00200491T patent/PT1004580E/en unknown
- 1994-07-01 PT PT00200492T patent/PT1004581E/en unknown
- 1994-07-01 PT PT94921439T patent/PT706521E/en unknown
- 1994-07-01 DK DK00200498T patent/DK1004572T3/en active
- 1994-07-01 AT AT94921439T patent/ATE225344T1/en active
- 1994-07-01 DE DE69431480T patent/DE69431480T2/en not_active Expired - Lifetime
- 1994-07-01 ES ES94921439T patent/ES2184765T3/en not_active Expired - Lifetime
- 1994-07-01 WO PCT/US1994/007411 patent/WO1995001348A2/en active IP Right Grant
- 1994-07-01 PL PL94312386A patent/PL180377B1/en not_active IP Right Cessation
- 1994-07-01 HU HU9600003A patent/HUT75312A/en unknown
- 1994-07-01 DE DE69434029T patent/DE69434029T2/en not_active Expired - Lifetime
-
1995
- 1995-12-29 FI FI956362A patent/FI114984B/en not_active IP Right Cessation
-
2000
- 2000-08-10 HK HK00104990A patent/HK1025770A1/en not_active IP Right Cessation
- 2000-08-10 HK HK00104989A patent/HK1025769A1/en not_active IP Right Cessation
- 2000-08-10 HK HK00104991A patent/HK1025765A1/en not_active IP Right Cessation
-
2004
- 2004-04-27 FI FI20040593A patent/FI20040593A/en not_active Application Discontinuation
-
2006
- 2006-02-16 JP JP2006039633A patent/JP2006188529A/en active Pending
- 2006-02-16 JP JP2006039629A patent/JP2006131647A/en active Pending
- 2006-02-16 JP JP2006039624A patent/JP4461107B2/en not_active Expired - Fee Related
- 2006-02-16 JP JP2006039637A patent/JP2006188530A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU96102001A (en) | IMIDES AS TNF ALPHA INHIBITORS | |
KR960703891A (en) | TNP α inhibitor imide (IMIDES AS INHIBITORS OF TNP ALPHA) | |
RU98105689A (en) | ALPHA TUMOR NECROSIS FACTOR INHIBITORS | |
RO82508B (en) | Process for preparing some 3-(1-pyperidinylalkyl)-4h-pyrido-(1, 2-a)-pyrimidin-4-one derivatives | |
EA200000637A1 (en) | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN-TYROSINKINAZ INHIBITORS | |
RU97112858A (en) | SUBSTITUTED IMIDES AS INHIBITORS | |
KR910011891A (en) | Peptide compound, preparation method thereof and pharmaceutical composition containing same | |
SE9601598D0 (en) | New process | |
ES2102154T3 (en) | THROMBIN INHIBITION. | |
NO20005714L (en) | Novel substituted cyclic compounds, process for their preparation and pharmaceutical compositions containing them | |
PL314136A1 (en) | Some condensed pyrrole carboxylanilides, novel class of cerebral receptor gaba ligands | |
GB2303851A (en) | Pharmaceutical diketopiperazine compounds | |
NO832923L (en) | PROCEDURE FOR PREPARING PHARMASOYYTIC ACTIVE 4- (3-TRIFLUOROMETHYLPHENYL) -1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | |
DE3876382D1 (en) | METHOD FOR PRODUCING DIANHYDROSORBITOLAETHER. | |
NO984740L (en) | Isatin derivatives such as acetylcholinesterase inhibitors and analgesics | |
PT73280A (en) | NEW IMIDAZOLE DERIVATIVES PROCESS FOR THEIR PREPARATION AND THESE PHARMACEUTICAL PRAPARATES CONTAINING | |
CA2094808A1 (en) | Oxysulfonyl urea acat inhibitors | |
FR2671349B1 (en) | NOVEL 1,4-DIHYDROPYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITION CONTAINING THEM. | |
DE68917569D1 (en) | 4-aminophenol derivatives and process for their preparation. | |
DE69221634T2 (en) | 5-piperazinylalkyl) -1,5-benzothiazepinone usable as calcium antagonists | |
FI922835A (en) | Process for the preparation of therapeutically active piperidine derivatives | |
NO20000750L (en) | Procedure for reducing platelet counts | |
ATE28871T1 (en) | DISUBSTITUTED PIPERIDINS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
AR008920A1 (en) | PROCESS FOR THE PREPARATION OF THE DERIVATIVES OF 2-AMINO-2-IMIDAXOLINE, GUANIDINE, AND 2-AMINO-3,4,5,6-TETRAHYDROPYRIDIMINE | |
AU2172688A (en) | Preparation of dien-1-ols, 9-hydroxydodec-10-enyl 1-tert-butyl ether and use thereof as an intermediate for synthesizing, 8,10-dodecadienol |